LONG-TERM RESULTS OF INTRAVITREAL RANIBIZUMAB, INTRAVITREAL RANIBIZUMAB WITH PHOTODYNAMIC THERAPY, AND INTRAVITREAL TRIAMCINOLONE WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To compare intravitreal ranibizumab, intravitreal ranibizumab plus photodynamic therapy (PDT), and intravitreal triamcinolone plus PDT in retinal angiomatous proliferation, presenting the results of a 3-year follow-up. Methods: Thirty-seven eyes of 37 patients with retinal angiomatous proliferation were randomized to 1 of the 3 groups. Group 1 (n = 13) received 3 monthly injections of 0.5 mg ranibizumab, Group 2 (n = 13) received 1 session of PDT and 3 monthly injections of ranibizumab, and Group 3 (n = 11) received 1 session of PDT and 1 injection of 4 mg triamcinolone. Retreatment, with the same therapeutic scheme in each group, was considered in case of persistence or recurrence of subretinal/intraretinal fluid. Results: Twelve patients in Groups 1 and 2 and 9 patients in Group 3 completed the 3-year follow-up. A total of 58% of patients in Group 1, 50% in Group 2, and 88.9% in Group 3 had the same or better visual acuity at the end of the follow-up (P = 0.081). Patients in Group 3 exhibited considerable improvement in visual acuity (P = 0.032) and statistically significant decrease in central retinal thickness (P < 0.0001) than the 2 other groups at the end of the follow-up. Also, the patients in Group 3 received on average the lowest number of injections (P < 0.0001). Of note, geographic atrophy mainly at the place of previous retinal angiomatous proliferation lesion was detected in 0% in Group 1, 25% in Group 2, and 55.6% in Group 3 (P = 0.203), while 33.3% of patients in Group 1 developed retinal scar. Conclusion: Treatment with ranibizumab or ranibizumab plus PDT resulted in stabilization of the disease, while treatment with IVT plus PDT achieved better results in terms of functional and anatomical features compared with the other groups. Our study compares three therapeutic modalities against retinal angiomatous proliferation. Treatment with ranibizumab or ranibizumab plus photodynamic therapy resulted in stabilization of the disease, while treatment with intravitreal triamcinolone plus photodynamic therapy achieved better results in terms of functional and anatomical features compared with the other groups.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but a more recent study reported that only one third of the RAP lesions treated with three 0.5-mg intravitreal injections of ranibizumab and followed up for 3 years developed retinal scarring.39”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [39]
Citations
Cites
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION
Yannuzzi, L. A., Negrão, S., IIDA, T., Carvalho, C., Rodriguez-Coleman, H., Slakter, J., Freund, K. B., Sorenson, J., Orlock, D., & Borodoker, N. (2012) · Retina · doi:10.1097/iae.0b013e31823f9b3b · Cited by 660 · cited 6×
“Retinal angiomatous proliferation accounts for 10% to 15% of all neovascular age-related macular degeneration in white patients and 4.5% in Japanese patients,2,3 but its natural course is believed to be worse 1181 than that of typical exudative age-related macular degeneration; therefore, its recognition is essential.…”
BackgroundInfluentialRETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION
YANNUZZI, L. A., NEGRÃO, S., IIDA, T., CARVALHO, C., RODRIGUEZ-COLEMAN, H., SLAKTER, J., FREUND, K. B., SORENSON, J., ORLOCK, D., & BORODOKER, N. (2001) · Retina · doi:10.1097/00006982-200110000-00003 · Cited by 659
Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese Patients
Maruko, I., Iida, T., Saito, M., Nagayama, D., & Saito, K. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.03.047 · Cited by 544
Bottoni, F. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1644 · Cited by 129
Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration
Cohen, S. Y., Creuzot-Garcher, C. P., Darmon, J., Desmettre, T. J., Korobelnik, J., Levrat, F., Quentel, G., Palies, S., Sanchez, A., de Gendre, A. S., et al. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.115501 · Cited by 124
Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment
Boscia, F., Furino, C., Sborgia, L., Reibaldi, M., & Sborgia, C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.06.072 · Cited by 92
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION
MEYERLE, C. B., FREUND, K. B., ITURRALDE, D., SPAIDE, R. F., SORENSON, J. A., SLAKTER, J. S., KLANCNIK, J. M., FISHER, Y. L., COONEY, M. J., & YANNUZZI, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318030ea80 · Cited by 88 · cited 6×
“Retinal angiomatous proliferation accounts for 10% to 15% of all neovascular age-related macular degeneration in white patients and 4.5% in Japanese patients,2,3 but its natural course is believed to be worse 1181 than that of typical exudative age-related macular degeneration; therefore, its recognition is essential.…”
BackgroundInfluentialGEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION
Mcbain, V. A., Kumari, R., Townend, J., & Lois, N. (2011) · Retina · doi:10.1097/iae.0b013e3181fe54c7 · Cited by 85
RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss
VIOLA, F., MASSACESI, A., ORZALESI, N., RATIGLIA, R., & STAURENGHI, G. (2009) · Retina · doi:10.1097/iae.0b013e3181a395cb · Cited by 79 · cited 1×
“” There is a controversy about which is the most appropriate treatment of RAP, although it is generally considered that RAP has a poor prognosis because it typically progresses to severe stages ending in a disciform scar.(12) Before the introduction of anti–vascular endothelial growth factor (anti-VEGF) agents, there…”
Background
Cited by
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
“5-mg intravitreal injections of ranibizumab and followed up for 3 years developed retinal scarring.(39) Although further investigation is warranted, these data suggest that anti-VEGF treatment prevents scar formation from RAP lesions.”
Local delivery of corticosteroids in clinical ophthalmology: A review
Fung, A. T.-C., Tran, T., Lim, L. L., Samarawickrama, C., Arnold, J., Gillies, M. C., Catt, C. J., Mitchell, L., Symons, R. C. A., Buttery, R., et al. (2019) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13702 · Cited by 129
Daniel, E., Shaffer, J., Ying, G., Grunwald, J. E., Martín, D., Jaffe, G. J., & Maguire, M. G. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.034 · Cited by 110
Retinal angiomatous proliferation
Tsai, A. S. H., Cheung, N., Gan, A. T. L., Jaffe, G. J., Sivaprasad, S., Wong, T. Y., & Cheung, C. M. G. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.01.008 · Cited by 82
“In a study with the longest follow up to-date (3 years), Rouvas et al compared the treatment effect of ranibizumab alone to PDT and ranibizumab to PDT and IVTA.(97) In this study that included all RAP stages, surprisingly, visual acuity improvement was only seen in the group treated with PDT and”
Metadata
- Authors
- Rouvas, A. A., Chatziralli, I. P., Theodossiadis, P. G., Moschos, M. M., Kotsolis, A. I., & Ladas, I. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Rouvas, Alexandros A.
- Theodossiadis, Panagiotis G.
- Venue
- Retina
- Published
- 2012-06
- Volume
- 32
- Issue
- 6
- Pages
- 1181-1189
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2074013967
- Cited by
- 30
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 4
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, photodynamic therapy, intravitreal triamcinolone acetonide, retinal angiomatous proliferation, geographic atrophy, retinal scarring, visual acuity, central retinal thickness, anti-VEGF therapy, long-term outcomes, subretinal fluid, intraretinal fluid, retreatment, anti-inflammatory therapy, anti-angiogenic therapy, choroidal neovascularization
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Photochemotherapy, Triamcinolone, Visual Acuity, Retinal Neovascularization, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.